TPM2 attenuates progression of prostate cancer by blocking PDLIM7-mediated nuclear translocation of YAP1
Authors:
Open Access
- 23 February 2023
- journal article
- research article
- Published by Springer Nature in Cell & Bioscience
- Vol. 13 (1) , 1-16
Abstract
Background: Prostate cancer (PCa) is a common malignant tumor of the genitourinary system. Clinical intervention in advanced PCa remains challenging. Tropomyosins 2 (TPM2) are actin-binding proteins and have been found as a biomarker candidate for certain cancers. However, no studies have explored the role of TPM2 in PCa and its regulatory mechanism. Methods: TPM2 expression was assessed in Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) PCa patient dataset. The effect of TPM2 on PCa progression was assessed in vitro and in vivo by quantifying proliferation, migration, invasion and tumor growth assays, and the mechanism of TPM2 in PCa progression was gradually revealed by Western blotting, immunoprecipitation, and immunofluorescence staining arrays. Results: TPM2 was found to be severely downregulated in tumor tissues of PCa patients compared with tumor-adjacent normal tissues. In vitro experiments revealed that TPM2 overexpression inhibited PCa cell proliferation, invasion and androgen-independent proliferation. Moreover, TPM2 overexpression inhibited the growth of subcutaneous xenograft tumors in vivo. Mechanistically, this effect was noted to be dependent on PDZ-binding motif of TPM2. TPM2 competed with YAP1 for binding to PDLIM7 through the PDZ-binding motif. The binding of TPM2 to PDLIM7 subsequently inhibited the nuclear transport function of PDLIM7 for YAP1. YAP1 sequestered in the cytoplasm phosphorylated at S127, resulting in its inactivation or degradation which in turn inhibited the expression of YAP1 downstream target genes. Conclusions: This study investigated the role of TPM2, PDLIM7, and YAP1 in PCa progression and castration resistance. TPM2 attenuates progression of PCa by blocking PDLIM7-mediated nuclear translocation of YAP1. Accordingly, targeting the expression or functional modulation of TPM2, PDLIM7, or YAP1 has the potential to be an effective therapeutic approach to reduce PCa proliferation and prevent the progression of castration-resistant prostate cancer (CRPC).Keywords
Funding Information
- National Natural Science Foundation of China (82072828, 81972381, 82173385)
This publication has 53 references indexed in Scilit:
- Tumor suppressors: enhancers or suppressors of regeneration?Development, 2013
- Using Proteomic Approach to Identify Tumor-Associated Proteins as Biomarkers in Human Esophageal Squamous Cell CarcinomaJournal of Proteome Research, 2011
- Roles for microRNAs in the regulation of cell adhesion moleculesJournal of Cell Science, 2011
- Expression of a novel tropomyosin isoform in axolotl heart and skeletal muscleJournal of Cellular Biochemistry, 2010
- Nuclear localization and pro‐apoptotic signaling of YAP2 require intact PDZ‐binding motifGenes to Cells, 2009
- Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth controlGenes & Development, 2007
- Quantification of PDZ Domain Specificity, Prediction of Ligand Affinity and Rational Design of Super-binding PeptidesJournal of Molecular Biology, 2004
- Tbx5 and Tbx4 transcription factors interact with a new chicken PDZ-LIM protein in limb and heart developmentDevelopmental Biology, 2004
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repositoryNucleic Acids Research, 2002
- Evolution of tropomyosin functional domains: Differential splicing and genomic constraintsJournal of Molecular Evolution, 1988